Skip to main content

Statin Side Effects: The Truth Revealed

Published on June 25, 2026, 8:02 a.m.
Statin Side Effects: The Truth Revealed

Topic: Health

A massive study found that most statin side effects are not caused by the drugs. Statins reduce bad cholesterol and lower heart attack risks. The study analyzed data from 23 major studies and found no significant increase in risk for most listed side effects.

Statin medications have been widely prescribed to reduce low-density lipoprotein (LDL) or 'bad' cholesterol, which can lead to heart attacks and strokes. Despite their effectiveness, concerns about possible side effects have led some patients to hesitate or stop treatment. To better understand the true risks, researchers analyzed data from 23 major randomized studies conducted by the Cholesterol Treatment Trialists' Collaboration.

The study found that people taking statins reported nearly the same rates of most symptoms as those taking a placebo. For instance, yearly reports of cognitive or memory problems were 0.2% among statin users and 0.2% among those on placebo. This means that while some people may experience these symptoms during treatment, the evidence does not show that statins are the cause.

The analysis found no statistically significant increase in risk linked to statins for most listed side effects, including memory loss or dementia, depression, sleep problems, erectile dysfunction, weight gain, nausea, fatigue, headache, and many other commonly cited concerns. However, there was a small rise of about 0.1% in abnormal liver blood test results among people taking statins.

Professor Christina Reith, the lead author of the study, said that statins are life-saving drugs used by hundreds of millions of people over the past 30 years. She added that concerns about the safety of statins have deterred many people who are at risk of severe disability or death from a heart attack or stroke.

The study also found that statins can slightly raise blood sugar levels, meaning that individuals already at high risk for diabetes may develop the condition somewhat sooner.

Why It Matters

This study matters because it provides reassurance to patients who are hesitant about taking statins due to concerns about side effects. In India, heart disease is a leading cause of death, and statins can be an effective way to reduce the risk of heart attacks and strokes.

Key Facts

  • The study analyzed data from 23 major randomized studies conducted by the Cholesterol Treatment Trialists' Collaboration.
  • People taking statins reported nearly the same rates of most symptoms as those taking a placebo.
  • There was no statistically significant increase in risk linked to statins for most listed side effects.
  • Statins can slightly raise blood sugar levels, which may affect individuals at high risk for diabetes.
  • The study found that only 4 out of 66 reported side effects were associated with taking statins.

Key Terms

Statin
A type of medication that reduces bad cholesterol and lowers the risk of heart attacks and strokes

Implications

This study matters because it provides reassurance to patients who are hesitant about taking statins due to concerns about side effects. In India, heart disease is a leading cause of death, and statins can be an effective way to reduce the risk of heart attacks and strokes.


Source: https://www.sciencedaily.com/releases/2026/02/260212025550.htm

Journal Reference:

  1. Christina Reith, Lisa Blackwell, Jonathan R Emberson, David Preiss, Enti Spata, Kelly Davies, Heather Halls, Charlie Harper, Lisa Holland, Kate Wilson, Robert Humphrey, Alistair J Roddick, Christopher P Cannon, Barry R Davis, Paul N Durrington, Shinya Goto, Graham A Hitman, G Kees Hovingh, Wolfgang Koenig, Vera Krane, Martin J Landray, Borislava Mihaylova, Connie Newman, Jeffrey L Probstfield, Marc S Sabatine, Naveed Sattar, Gregory G Schwartz, Andrew M Tonkin, Harvey D White, Jane Armitage, Anthony Keech, John Simes, Rory Collins, Colin Baigent, Elizabeth Barnes, Jordan Fulcher, William G Herrington, Adrienne Kirby, Rachel O\'Connell, Pierre Amarenco, Hiroyuki Arashi, Philip Barter, D John Betteridge, Michael Blazing, Gerard J Blauw, Marc Bonaca, Jackie Bosch, Louise Bowman, Eugene Braunwald, Richard Bulbulia, Robert Byington, Robert Clarke, Michael Clearfield, Stuart Cobbe, Helen M Colhoun, Björn Dahlöf, James de Lemos, John R Downs, Bengt Fellström, Lawrence Fine, Marcus Flather, Ian Ford, Maria Grazia Franzosi, John Fuller, Curt Furberg, Robert Glynn, Uri Goldbourt, David Gordon, Antonio Gotto, Jr, Richard Grimm, Ajay Gupta, C Morton Hawkins, Richard Haynes, Hallvard Holdaas, Jemma Hopewell, Alan Jardine, J Wouter Jukema, John JP Kastelein, Sharon Kean, Patricia Kearney, George Kitas, John Kjekshus, Genell Knatterud, Robert H Knopp, John Kjekshus, Michael Koren, John LaRosa, Roberto Latini, Eva Lonn, Donata Lucci, Jean MacFadyen, Peter Macfarlane, Stephen MacMahon, Aldo Maggioni, Roberto Marchioli, Ian Marschner, Lemuel Moyé, Heather Murray, Sabina Murphy, Andrew Neil, Enrico B Nicolis, Chris Packard, Sarah Parish, Terje R Pedersen, Richard Peto, Marc Pfeffer, Neil Poulter, Sara Pressel, Mahboob Rahman, Paul M Ridker, Michele Robertson, Frank Sacks, Roland Schmieder, Patrick W Serruys, Peter Sever, John Shaw, James Shepherd, Lara Simpson, Peter Sleight, Liam Smeeth, Luigi Tavazzi, Jonathan Tobert, Gianni Tognoni, Stella Trompet, John Varigos, Christoph Wanner, Hans Wedel, Stephen Weis, K Michael Welch, John Wikstrand, Lars Wilhelmsen, Stephen Wiviott, Junichi Yamaguchi, Robin Young, Salim Yusuf, Faiez Zannad. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. The Lancet, 2026; DOI: 10.1016/S0140-6736(25)01578-8

Leave a Comment

Name
Email
Body
... ...

Get Exclusive Insights

with Every Issue

JoinShalyamNewsletter

Stay ahead in education, research, and innovation—straight to your inbox.